SB-269,970

SB-269,970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It was previously believed to act as a selective 5-HT7 receptor antagonist (or possibly inverse agonist), but a subsequent discovery showed that it also potently blocks the α2-adrenergic receptor. The new finding has raised significant concerns about studies using SB-269,970 as a specific serotonin receptor antagonist.

SB-269,970 is used to study the 5-HT7 receptors which are thought to be involved in the function of several areas of the brain such as the hippocampus and thalamus, and regulation of dopamine release in the ventral tegmental area. Possible therapeutic uses for SB-269,970 and other 5-HT7 antagonists include the treatment of anxiety and depression, and nootropic effects have also been noted in animal studies.